Generic EpiPen to Hit Mylan (MYL) EPS by a Modest 2% - Leerink

August 29, 2016 10:08 AM EDT
Get Alerts MYL Hot Sheet
Price: $37.07 +0.32%

Rating Summary:
    12 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade MYL Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Leerink Partners analyst Jason Gerberry weighed in on Mylan (NASDAQ: MYL) after the company announced the launch of a generic version of its EpiPen amid price scrutiny.

Gerberry estimates the launch of an EpiPen authorized generic (AG) will have a 8-14% impact on the '16-17E EpiPen sales estimates and a modest impact (~2%) on estimated EPS forecasts.

The firm's analysis assumes: (1) EpiPen TRx volume growth of 3% Y/Y in '17E; (2) the AG captures ~35% and ~65% of 4Q16E and FY 2017E EpiPen TRx and; (3) net pricing of $344/TRx and $285/TRx for the brand and AG respectively.

The firm maintained an Outperform rating and price target of $55 on MYL.

For an analyst ratings summary and ratings history on Mylan click here. For more ratings news on Mylan click here.

Shares of Mylan closed at $43.03 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Add Your Comment